GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GlaxoSmithKline (GSK) has recently completed a clinical study titled ‘A Randomized, Non-inferiority, Double-blind, Controlled, Single-dose, 2-way Cross-over Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Metered Dose Inhalers in Adults Aged 18-45 With Mild Asthma.’ The study aims to evaluate the potential airway sensitivity reactions caused by two propellants, HFA-152a and HFA-134a, when delivered through inhalers, with a focus on developing a more environmentally friendly propellant option.
The interventions tested in this study are the propellants HFA-152a and HFA-134a, both administered via oral inhalation. HFA-152a is being investigated as a low carbon footprint alternative to HFA-134a, aiming to reduce the environmental impact of inhaler propellants.
This interventional study utilized a randomized, crossover design with double masking, involving both participants and investigators. The primary purpose of the study was treatment, focusing on comparing the airway sensitivity reactions between the two propellants.
The study commenced on March 11, 2025, with its primary completion and last update recorded on July 2, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for data analysis and potential publication of results.
The completion of this study could have significant market implications for GSK, potentially enhancing investor sentiment by positioning the company as a leader in environmentally sustainable healthcare solutions. The development of a low carbon footprint propellant could set GSK apart from competitors, aligning with global sustainability trends and potentially impacting stock performance positively.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.